Show
Sort by
-
Prostate magnetic resonance imaging provides limited incremental value over the Memorial Sloan Kettering Cancer Center preradical prostatectomy nomogram : editorial comment
-
Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence : a prospective, randomized, multicenter phase II trial
-
Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer : comparing definitions of CHAARTED and LATITUDE trial
-
MRI in prostate cancer diagnosis, surgical or radiation treatment, focal therapy, active surveillance and follow-up
-
4 Weeks versus 5 weeks of hypofractionated high-dose radiation therapy as primary therapy for prostate cancer : interim safety analysis of a randomized phase 3 trial
-
Release of urinary extracellular vesicles in prostate cancer is associated with altered urinary N-glycosylation profile
-
The independent oncological role for cytoreductive nephrectomy in metastatic renal cell carcinoma : prognostic features in the era of targeted therapies
-
Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer : comparing the definitions of CHAARTED and LATITUDE trial
-
Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy
-
Dynamic contrast-enhanced imaging has limited added value over T2-weighted imaging and diffusion-weighted imaging when using PI-RADSv2 for diagnosis of clinically significant prostate cancer in patients with elevated PSA